Cardiotoxicity of Adjuvant Trastuzumab
Launched by ROYAL PRINCE ALFRED HOSPITAL, SYDNEY, AUSTRALIA · Mar 6, 2009
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female 18 years or older
- • Histologically confirmed, completely excised invasive breast cancer with Her-2 overexpression
- • Primary surgery less than twelve weeks prior to registration
- • LVEF\>50% as assessed by transthoracic echocardiogram or gated heart pool scan
- • Eastern Cooperative Oncology Group Performance Status 0-2
- • Adjuvant systemic treatment plan comprises at least three cycles of anthracycline chemotherapy AND 52 weeks of trastuzumab
- • Before patient registration, informed consent must be given according to local regulations.
- Exclusion Criteria:
- • Pregnancy
- • Distant metastases from breast cancer
- • Any systemic chemotherapy prior to study entry
About Royal Prince Alfred Hospital, Sydney, Australia
Royal Prince Alfred Hospital (RPAH) in Sydney, Australia, is a leading tertiary healthcare facility renowned for its commitment to high-quality patient care, innovative research, and medical education. As a prominent clinical trial sponsor, RPAH engages in cutting-edge studies across various medical disciplines, aiming to advance treatment options and improve patient outcomes. The hospital's multidisciplinary team of experienced clinicians and researchers collaborates with national and international partners to conduct rigorous trials that adhere to the highest ethical and scientific standards, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brisbane, Queensland, Australia
Geelong, Victoria, Australia
Sydney, New South Wales, Australia
Tweed Heads, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Warnambool, Victoria, Australia
Perth, Western Australia, Australia
Patients applied
Trial Officials
Jane Beith, MBBS FRACP PhD
Study Director
Sydney South West Area Health Service (Royal Prince Alfred Hospital)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials